000 02740cam a2200337 a 4500
003 EG-GiCUC
005 20250223032143.0
008 190103s2018 ua h f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aM.Sc
099 _aCai01.11.18.M.Sc.2018.Na.R
100 0 _aNawal Eltayeb Omer Mohamed
245 1 0 _aRole of epigenetic changes in the pathogenesis, prognosis and management of hematopoietic malignancies /
_cNawal Eltayeb Omer ; Supervised Mona Mohammad Elkassas , Asmaa Mohammad Abdelhameed
246 1 5 _aدور التخلق المتوالى فى تخليق سرطانات الدم و التكهن بمالآتها و علاجها
260 _aCairo :
_bNawal Eltayeb Omer Mohamed ,
_c2018
300 _a141 P. :
_bfacsimiles ;
_c25cm
502 _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
520 _aBackground: Hematopoietic malignancies are among the top ten cancers worldwide, despite the progress that has been made in the treatment of hematologic malignancies overall survival rates are still low and most patients still have a shorter lifespan. In recent years, accumulating data appreciate the role of epigenetics in the pathogenesis of hematologic malignancies. Objectives: Our objective was to search the literature about the role of epigenetic changes in pathogenesis and prognosis of hematologic malignancies and see how understanding of this role can be used for better management of hematologic malignancies. Methods: We comprehensively reviewed electronic databases including google, google scholar, PubMed and cochrane lLibrary about the role of epigenetic changes in hematologic malignancies. Results and conclusion: Epigenetic changes play a fundamental role in pathogenesis of hematologic malignancies. Mutations involving epigenetic regulating genes like DNMTs, TET1/2, EZH2, IDH1/2 and ASXL1 recurrently occur in hematologic malignancies and sometimes these mutations represent the drive event in the development of hematologic malignancies. Presence of these changes in hematologic malignancies indicates poor prognosis, epigenetic drugs are very promising in treating hematologic malignancies. More researches in this field hopefully will lead to production of more efficient treatments for hematologic malignancies
530 _aIssued also as CD
653 4 _aCancer
653 4 _aEpigenetics
653 4 _aHematologic malignancies
700 0 _aAsmaa Mohammad Abdelhameed ,
_eSupervisor
700 0 _aMona Mohammad Elkassas ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c69392
_d69392